Viruses and Bioinformatics from Virology.uvic.ca
88.0K views | +7 today
Follow
Viruses and Bioinformatics from Virology.uvic.ca
Virus and bioinformatics articles with some microbiology and immunology thrown in for good measure
Your new post is loading...
Your new post is loading...
Scooped by Chris Upton + helpers
Scoop.it!

Bilirubin: An Endogenous Molecule with Antiv... [Front Pharmacol. 2012] - PubMed - NCBI

Bilirubin-IX-alpha (BR) is the final product of heme metabolism through the heme oxygenase/biliverdin reductase (HO/BVR) system. Previous papers reported on the microbicidal effects of the HO by-products biliverdin-IX-alpha, carbon monoxide and iron, through either direct or indirect mechanisms.
more...
No comment yet.
Scooped by Michael Wolfe
Scoop.it!

Should Science Pull the Trigger on Antiviral Drugs—That Can Blast the Common Cold?

Should Science Pull the Trigger on Antiviral Drugs—That Can Blast the Common Cold? | Viruses and Bioinformatics from Virology.uvic.ca | Scoop.it
There's a moment in the history of medicine that's so cinematic it's a wonder no one has put it in a Hollywood film. The scene is a London l...
more...
No comment yet.
Scooped by Chris Upton + helpers
Scoop.it!

In Vitro Characterization of a Nineteenth-Century Therapy for Smallpox

In Vitro Characterization of a Nineteenth-Century Therapy for Smallpox | Viruses and Bioinformatics from Virology.uvic.ca | Scoop.it
In the nineteenth century, smallpox ravaged through the United States and Canada. At this time, a botanical preparation, derived from the carnivorous plant Sarracenia purpurea, was proclaimed as being a successful therapy for smallpox infections.
more...
No comment yet.
Rescooped by Chris Upton + helpers from Virology News
Scoop.it!

Antivirals for Treatment of Influenza: A Systematic Review and Meta-analysis of Observational Studies

Antivirals for Treatment of Influenza: A Systematic Review and Meta-analysis of Observational Studies | Viruses and Bioinformatics from Virology.uvic.ca | Scoop.it

Meta-analyses of the few studies providing effects with adjustment for confounders suggest that in high-risk populations, oral oseltamivir may reduce mortality (odds ratio, 0.23 [95% CI, 0.13 to 0.43]; low-quality evidence), hospitalization (odds ratio, 0.75 [CI, 0.66 to 0.89]; low-quality evidence), and duration of symptoms (33 hours [CI, 21 to 45 hours]; very low–quality evidence) compared with no treatment. Earlier treatment with oseltamivir was generally associated with better outcomes. Inhaled zanamivir may lead to shorter symptom duration (23 hours [CI, 17 to 28 hours]; moderate-quality evidence) and fewer hospitalizations (odds ratio, 0.66 [CI, 0.37 to 1.18]) but more complications than no treatment. Direct comparison of oral oseltamivir and inhaled zanamivir suggests no important differences in key outcomes. Data from 1 study suggests that oral amantadine may reduce mortality and pneumonia associated with influenza A. No included study evaluated rimantadine.

 

Image courtesy of Russell Kightley Media


Via Ed Rybicki
more...
No comment yet.